The FDA protected a single dose of Johnson & Johnson’s de la vacuna against COVID-19

Washington. The vaccine of a single dose of Johnson & Johnson (J&J) protects against COVID-19, an analysis carried out by stadium regulators in this market that prepares the scenario for a final decision on a new vaccine more easy to use to eradicate the pandemic.

The Food and Drug Administration (FDA) confirms to the general public that the vaccine is approximately 66% effective in preventing COVID-19 from getting serious. The agency also says that Janssen’s injection, J & J’s pharmaceutical division, is safe to use.

This is only a step in the FDA’s evaluation of a third vacancy option for the United States.

This is a great place to stay, especially with homeowners of your choice. Armed with this advice, it is hoped that the FDA will make a final decision and issue of days.

J&J tested its 44,000-person single dose option in the United States, Latin America and South Africa. Although different mutated versions of the virus are circulating in different countries, investigators are analyzing the geographical results.

J&J predicts that the vaccine will work better in the United States: 72% effective against COVID-19 moderate to severe, compared with 66% in Latin America and 57% in South Africa.

Without embarrassment, all of these countries were highly effective against the most severe symptoms, and the first results of the study showed no hospitalizations and deaths from 28 days after the evacuation.